nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—NFKB1—psoriasis	0.36	0.765	CbGaD
Thalidomide—TNF—psoriasis	0.11	0.235	CbGaD
Thalidomide—CYP1A1—Clobetasol propionate—psoriasis	0.0544	0.184	CbGbCtD
Thalidomide—CYP1A1—Methoxsalen—psoriasis	0.0286	0.0967	CbGbCtD
Thalidomide—CYP3A5—Beclomethasone—psoriasis	0.0247	0.0837	CbGbCtD
Thalidomide—CYP1A2—Clobetasol propionate—psoriasis	0.0243	0.0822	CbGbCtD
Thalidomide—PTGS2—Triamcinolone—psoriasis	0.0194	0.0658	CbGbCtD
Thalidomide—CYP1A1—Cholecalciferol—psoriasis	0.0189	0.0641	CbGbCtD
Thalidomide—PTGS2—Betamethasone—psoriasis	0.0167	0.0564	CbGbCtD
Thalidomide—CYP1A2—Methoxsalen—psoriasis	0.0128	0.0432	CbGbCtD
Thalidomide—CYP3A5—Mycophenolate mofetil—psoriasis	0.00985	0.0333	CbGbCtD
Thalidomide—PTGS2—Dexamethasone—psoriasis	0.0097	0.0328	CbGbCtD
Thalidomide—CYP2C19—Cholecalciferol—psoriasis	0.00916	0.031	CbGbCtD
Thalidomide—CYP1A1—Dexamethasone—psoriasis	0.00819	0.0277	CbGbCtD
Thalidomide—CYP3A5—Hydrocortisone—psoriasis	0.0079	0.0268	CbGbCtD
Thalidomide—CYP2C9—Cholecalciferol—psoriasis	0.00762	0.0258	CbGbCtD
Thalidomide—CYP3A5—Cyclosporine—psoriasis	0.00746	0.0253	CbGbCtD
Thalidomide—CYP2C19—Prednisone—psoriasis	0.00635	0.0215	CbGbCtD
Thalidomide—CYP2E1—Dexamethasone—psoriasis	0.00633	0.0214	CbGbCtD
Thalidomide—CYP2C19—Cyclosporine—psoriasis	0.00602	0.0204	CbGbCtD
Thalidomide—CYP2C9—Cyclosporine—psoriasis	0.00501	0.0169	CbGbCtD
Thalidomide—CYP3A5—Dexamethasone—psoriasis	0.00492	0.0166	CbGbCtD
Thalidomide—CYP2C19—Dexamethasone—psoriasis	0.00397	0.0134	CbGbCtD
Thalidomide—CYP2C9—Dexamethasone—psoriasis	0.0033	0.0112	CbGbCtD
Thalidomide—FGFR2—skin epidermis—psoriasis	0.00173	0.216	CbGeAlD
Thalidomide—Pomalidomide—TNF—psoriasis	0.00154	1	CrCbGaD
Thalidomide—PTGS2—skeletal joint—psoriasis	0.00108	0.135	CbGeAlD
Thalidomide—PTGS2—synovial membrane of synovial joint—psoriasis	0.000821	0.102	CbGeAlD
Thalidomide—CYP1A1—skin epidermis—psoriasis	0.000628	0.0782	CbGeAlD
Thalidomide—NFKB1—tendon—psoriasis	0.000545	0.0678	CbGeAlD
Thalidomide—FGFR2—skin of body—psoriasis	0.000537	0.0669	CbGeAlD
Thalidomide—PTGS2—skin epidermis—psoriasis	0.000527	0.0656	CbGeAlD
Thalidomide—CRBN—tendon—psoriasis	0.000456	0.0568	CbGeAlD
Thalidomide—PTGS1—endothelium—psoriasis	0.0004	0.0498	CbGeAlD
Thalidomide—PTGS2—endothelium—psoriasis	0.000382	0.0476	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000356	0.157	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000285	0.126	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000277	0.122	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000215	0.0948	CbGdCrCtD
Thalidomide—CYP1A1—skin of body—psoriasis	0.000194	0.0242	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000172	0.076	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000172	0.076	CbGdCrCtD
Thalidomide—PTGS1—skin of body—psoriasis	0.000171	0.0213	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000167	0.0738	CbGdCrCtD
Thalidomide—PTGS2—skin of body—psoriasis	0.000163	0.0203	CbGeAlD
Thalidomide—CYP2E1—tendon—psoriasis	0.000135	0.0168	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.00013	0.0574	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.00013	0.0574	CbGdCrCtD
Thalidomide—PTGS1—tendon—psoriasis	0.00013	0.0162	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000127	0.0561	CbGdCrCtD
Thalidomide—PTGS2—tendon—psoriasis	0.000124	0.0155	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	7.85e-05	0.0346	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	7.85e-05	0.0346	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	7.67e-05	0.0338	CbGdCrCtD
Thalidomide—Vomiting—Mycophenolic acid—psoriasis	2.47e-05	0.000181	CcSEcCtD
Thalidomide—Discomfort—Betamethasone—psoriasis	2.46e-05	0.00018	CcSEcCtD
Thalidomide—Discomfort—Dexamethasone—psoriasis	2.46e-05	0.00018	CcSEcCtD
Thalidomide—Dyspepsia—Hydrocortisone—psoriasis	2.46e-05	0.00018	CcSEcCtD
Thalidomide—Rash—Mycophenolic acid—psoriasis	2.45e-05	0.00018	CcSEcCtD
Thalidomide—Dermatitis—Mycophenolic acid—psoriasis	2.45e-05	0.000179	CcSEcCtD
Thalidomide—Pain—Prednisolone—psoriasis	2.45e-05	0.000179	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—psoriasis	2.45e-05	0.000179	CcSEcCtD
Thalidomide—Urticaria—Mycophenolate mofetil—psoriasis	2.44e-05	0.000179	CcSEcCtD
Thalidomide—Headache—Mycophenolic acid—psoriasis	2.44e-05	0.000178	CcSEcCtD
Thalidomide—Decreased appetite—Hydrocortisone—psoriasis	2.43e-05	0.000178	CcSEcCtD
Thalidomide—Pharyngitis—Methotrexate—psoriasis	2.43e-05	0.000178	CcSEcCtD
Thalidomide—Abdominal pain—Mycophenolate mofetil—psoriasis	2.43e-05	0.000178	CcSEcCtD
Thalidomide—Body temperature increased—Mycophenolate mofetil—psoriasis	2.43e-05	0.000178	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—psoriasis	2.42e-05	0.000177	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.41e-05	0.000177	CcSEcCtD
Thalidomide—Fatigue—Hydrocortisone—psoriasis	2.41e-05	0.000177	CcSEcCtD
Thalidomide—Vision blurred—Prednisone—psoriasis	2.4e-05	0.000176	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—psoriasis	2.4e-05	0.000176	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.4e-05	0.000176	CcSEcCtD
Thalidomide—Pain—Hydrocortisone—psoriasis	2.39e-05	0.000175	CcSEcCtD
Thalidomide—Oedema—Betamethasone—psoriasis	2.39e-05	0.000175	CcSEcCtD
Thalidomide—Oedema—Dexamethasone—psoriasis	2.39e-05	0.000175	CcSEcCtD
Thalidomide—Insomnia—Triamcinolone—psoriasis	2.38e-05	0.000174	CcSEcCtD
Thalidomide—Infection—Dexamethasone—psoriasis	2.37e-05	0.000174	CcSEcCtD
Thalidomide—Infection—Betamethasone—psoriasis	2.37e-05	0.000174	CcSEcCtD
Thalidomide—Ill-defined disorder—Prednisone—psoriasis	2.36e-05	0.000173	CcSEcCtD
Thalidomide—Paraesthesia—Triamcinolone—psoriasis	2.36e-05	0.000173	CcSEcCtD
Thalidomide—Feeling abnormal—Prednisolone—psoriasis	2.36e-05	0.000173	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—psoriasis	2.36e-05	0.000173	CcSEcCtD
Thalidomide—Anaemia—Prednisone—psoriasis	2.36e-05	0.000173	CcSEcCtD
Thalidomide—Shock—Betamethasone—psoriasis	2.35e-05	0.000172	CcSEcCtD
Thalidomide—Shock—Dexamethasone—psoriasis	2.35e-05	0.000172	CcSEcCtD
Thalidomide—Dyspnoea—Triamcinolone—psoriasis	2.35e-05	0.000172	CcSEcCtD
Thalidomide—Nervous system disorder—Dexamethasone—psoriasis	2.34e-05	0.000172	CcSEcCtD
Thalidomide—Nervous system disorder—Betamethasone—psoriasis	2.34e-05	0.000172	CcSEcCtD
Thalidomide—Agitation—Prednisone—psoriasis	2.34e-05	0.000172	CcSEcCtD
Thalidomide—Thrombocytopenia—Betamethasone—psoriasis	2.34e-05	0.000171	CcSEcCtD
Thalidomide—Thrombocytopenia—Dexamethasone—psoriasis	2.34e-05	0.000171	CcSEcCtD
Thalidomide—Tachycardia—Dexamethasone—psoriasis	2.33e-05	0.000171	CcSEcCtD
Thalidomide—Tachycardia—Betamethasone—psoriasis	2.33e-05	0.000171	CcSEcCtD
Thalidomide—Angioedema—Prednisone—psoriasis	2.33e-05	0.000171	CcSEcCtD
Thalidomide—Hypersensitivity—Cyclosporine—psoriasis	2.32e-05	0.00017	CcSEcCtD
Thalidomide—Dyspepsia—Triamcinolone—psoriasis	2.32e-05	0.00017	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—psoriasis	2.31e-05	0.00017	CcSEcCtD
Thalidomide—Nausea—Mycophenolic acid—psoriasis	2.31e-05	0.000169	CcSEcCtD
Thalidomide—Hyperhidrosis—Dexamethasone—psoriasis	2.31e-05	0.000169	CcSEcCtD
Thalidomide—Hyperhidrosis—Betamethasone—psoriasis	2.31e-05	0.000169	CcSEcCtD
Thalidomide—Feeling abnormal—Hydrocortisone—psoriasis	2.3e-05	0.000169	CcSEcCtD
Thalidomide—Malaise—Prednisone—psoriasis	2.3e-05	0.000168	CcSEcCtD
Thalidomide—Vertigo—Prednisone—psoriasis	2.29e-05	0.000168	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—psoriasis	2.29e-05	0.000168	CcSEcCtD
Thalidomide—Gastrointestinal pain—Hydrocortisone—psoriasis	2.29e-05	0.000168	CcSEcCtD
Thalidomide—Syncope—Prednisone—psoriasis	2.29e-05	0.000167	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—psoriasis	2.28e-05	0.000167	CcSEcCtD
Thalidomide—Anorexia—Betamethasone—psoriasis	2.28e-05	0.000167	CcSEcCtD
Thalidomide—Anorexia—Dexamethasone—psoriasis	2.28e-05	0.000167	CcSEcCtD
Thalidomide—Urticaria—Prednisolone—psoriasis	2.27e-05	0.000167	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—psoriasis	2.27e-05	0.000166	CcSEcCtD
Thalidomide—Fatigue—Triamcinolone—psoriasis	2.27e-05	0.000166	CcSEcCtD
Thalidomide—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.26e-05	0.000166	CcSEcCtD
Thalidomide—Asthenia—Cyclosporine—psoriasis	2.26e-05	0.000165	CcSEcCtD
Thalidomide—Pain—Triamcinolone—psoriasis	2.25e-05	0.000165	CcSEcCtD
Thalidomide—Loss of consciousness—Prednisone—psoriasis	2.24e-05	0.000164	CcSEcCtD
Thalidomide—Hypotension—Betamethasone—psoriasis	2.23e-05	0.000164	CcSEcCtD
Thalidomide—Hypotension—Dexamethasone—psoriasis	2.23e-05	0.000164	CcSEcCtD
Thalidomide—Pruritus—Cyclosporine—psoriasis	2.23e-05	0.000163	CcSEcCtD
Thalidomide—Urticaria—Hydrocortisone—psoriasis	2.22e-05	0.000163	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—psoriasis	2.22e-05	0.000163	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—psoriasis	2.21e-05	0.000162	CcSEcCtD
Thalidomide—Body temperature increased—Hydrocortisone—psoriasis	2.21e-05	0.000162	CcSEcCtD
Thalidomide—Abdominal pain—Hydrocortisone—psoriasis	2.21e-05	0.000162	CcSEcCtD
Thalidomide—Convulsion—Prednisone—psoriasis	2.21e-05	0.000162	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.21e-05	0.000258	CbGpPWpGaD
Thalidomide—Mediastinal disorder—Methotrexate—psoriasis	2.21e-05	0.000162	CcSEcCtD
Thalidomide—Asthenia—Mycophenolate mofetil—psoriasis	2.2e-05	0.000161	CcSEcCtD
Thalidomide—Hypertension—Prednisone—psoriasis	2.2e-05	0.000161	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	2.2e-05	0.000257	CbGpPWpGaD
Thalidomide—Chills—Methotrexate—psoriasis	2.2e-05	0.000161	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—HLA-B—psoriasis	2.18e-05	0.000255	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	2.18e-05	0.000255	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.18e-05	0.000159	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Betamethasone—psoriasis	2.18e-05	0.000159	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—JUN—psoriasis	2.18e-05	0.000255	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD8A—psoriasis	2.17e-05	0.000254	CbGpPWpGaD
Thalidomide—Pruritus—Mycophenolate mofetil—psoriasis	2.17e-05	0.000159	CcSEcCtD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—IL6—psoriasis	2.17e-05	0.000254	CbGpPWpGaD
Thalidomide—Myalgia—Prednisone—psoriasis	2.17e-05	0.000159	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—psoriasis	2.17e-05	0.000159	CcSEcCtD
Thalidomide—Feeling abnormal—Triamcinolone—psoriasis	2.17e-05	0.000159	CcSEcCtD
Thalidomide—Anxiety—Prednisone—psoriasis	2.16e-05	0.000158	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—psoriasis	2.16e-05	0.000158	CcSEcCtD
Thalidomide—Insomnia—Dexamethasone—psoriasis	2.16e-05	0.000158	CcSEcCtD
Thalidomide—Insomnia—Betamethasone—psoriasis	2.16e-05	0.000158	CcSEcCtD
Thalidomide—PTGS1—Metabolism—CYP2S1—psoriasis	2.16e-05	0.000253	CbGpPWpGaD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.15e-05	0.000158	CcSEcCtD
Thalidomide—Diarrhoea—Cyclosporine—psoriasis	2.15e-05	0.000158	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.15e-05	0.000251	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFIH1—psoriasis	2.15e-05	0.000251	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-C—psoriasis	2.14e-05	0.000251	CbGpPWpGaD
Thalidomide—Paraesthesia—Dexamethasone—psoriasis	2.14e-05	0.000157	CcSEcCtD
Thalidomide—Paraesthesia—Betamethasone—psoriasis	2.14e-05	0.000157	CcSEcCtD
Thalidomide—Discomfort—Prednisone—psoriasis	2.14e-05	0.000157	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—psoriasis	2.14e-05	0.000157	CcSEcCtD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—psoriasis	2.14e-05	0.000251	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—LEP—psoriasis	2.13e-05	0.00025	CbGpPWpGaD
Thalidomide—Malnutrition—Methotrexate—psoriasis	2.13e-05	0.000156	CcSEcCtD
Thalidomide—NFKB1—Immune System—TNFAIP3—psoriasis	2.12e-05	0.000248	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.11e-05	0.000247	CbGpPWpGaD
Thalidomide—Hypersensitivity—Prednisolone—psoriasis	2.11e-05	0.000155	CcSEcCtD
Thalidomide—Dyspepsia—Betamethasone—psoriasis	2.1e-05	0.000154	CcSEcCtD
Thalidomide—Dyspepsia—Dexamethasone—psoriasis	2.1e-05	0.000154	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	2.1e-05	0.000246	CbGpPWpGaD
Thalidomide—Diarrhoea—Mycophenolate mofetil—psoriasis	2.1e-05	0.000154	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-B—psoriasis	2.09e-05	0.000245	CbGpPWpGaD
Thalidomide—Urticaria—Triamcinolone—psoriasis	2.09e-05	0.000153	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—psoriasis	2.09e-05	0.000153	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—TP53—psoriasis	2.08e-05	0.000244	CbGpPWpGaD
Thalidomide—Body temperature increased—Triamcinolone—psoriasis	2.08e-05	0.000152	CcSEcCtD
Thalidomide—Dizziness—Cyclosporine—psoriasis	2.08e-05	0.000152	CcSEcCtD
Thalidomide—Oedema—Prednisone—psoriasis	2.08e-05	0.000152	CcSEcCtD
Thalidomide—Decreased appetite—Dexamethasone—psoriasis	2.08e-05	0.000152	CcSEcCtD
Thalidomide—Decreased appetite—Betamethasone—psoriasis	2.08e-05	0.000152	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.07e-05	0.000242	CbGpPWpGaD
Thalidomide—Infection—Prednisone—psoriasis	2.07e-05	0.000151	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—HLA-B—psoriasis	2.07e-05	0.000242	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD8A—psoriasis	2.06e-05	0.000241	CbGpPWpGaD
Thalidomide—Gastrointestinal disorder—Dexamethasone—psoriasis	2.06e-05	0.000151	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Betamethasone—psoriasis	2.06e-05	0.000151	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TP53—psoriasis	2.06e-05	0.000241	CbGpPWpGaD
Thalidomide—Back pain—Methotrexate—psoriasis	2.06e-05	0.000151	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—IL6—psoriasis	2.06e-05	0.000241	CbGpPWpGaD
Thalidomide—Hypersensitivity—Hydrocortisone—psoriasis	2.06e-05	0.000151	CcSEcCtD
Thalidomide—Fatigue—Dexamethasone—psoriasis	2.06e-05	0.000151	CcSEcCtD
Thalidomide—Fatigue—Betamethasone—psoriasis	2.06e-05	0.000151	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.05e-05	0.00024	CbGpPWpGaD
Thalidomide—Shock—Prednisone—psoriasis	2.05e-05	0.00015	CcSEcCtD
Thalidomide—Pain—Betamethasone—psoriasis	2.04e-05	0.00015	CcSEcCtD
Thalidomide—Pain—Dexamethasone—psoriasis	2.04e-05	0.00015	CcSEcCtD
Thalidomide—Nervous system disorder—Prednisone—psoriasis	2.04e-05	0.000149	CcSEcCtD
Thalidomide—FGFR2—Immune System—HLA-C—psoriasis	2.04e-05	0.000238	CbGpPWpGaD
Thalidomide—Tachycardia—Prednisone—psoriasis	2.03e-05	0.000149	CcSEcCtD
Thalidomide—Dizziness—Mycophenolate mofetil—psoriasis	2.03e-05	0.000149	CcSEcCtD
Thalidomide—Skin disorder—Prednisone—psoriasis	2.02e-05	0.000148	CcSEcCtD
Thalidomide—PTGS2—Metabolism—NDUFA5—psoriasis	2.01e-05	0.000236	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	2.01e-05	0.000236	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Prednisone—psoriasis	2.01e-05	0.000147	CcSEcCtD
Thalidomide—FGFR2—Immune System—TNFAIP3—psoriasis	2.01e-05	0.000235	CbGpPWpGaD
Thalidomide—Vision blurred—Methotrexate—psoriasis	2.01e-05	0.000147	CcSEcCtD
Thalidomide—Asthenia—Hydrocortisone—psoriasis	2.01e-05	0.000147	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2e-05	0.000234	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL6—psoriasis	2e-05	0.000234	CbGpPWpGaD
Thalidomide—Vomiting—Cyclosporine—psoriasis	2e-05	0.000147	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—HLA-B—psoriasis	1.98e-05	0.000232	CbGpPWpGaD
Thalidomide—Rash—Cyclosporine—psoriasis	1.98e-05	0.000145	CcSEcCtD
Thalidomide—Anorexia—Prednisone—psoriasis	1.98e-05	0.000145	CcSEcCtD
Thalidomide—Dermatitis—Cyclosporine—psoriasis	1.98e-05	0.000145	CcSEcCtD
Thalidomide—Pruritus—Hydrocortisone—psoriasis	1.98e-05	0.000145	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—psoriasis	1.98e-05	0.000145	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—IL6—psoriasis	1.97e-05	0.000231	CbGpPWpGaD
Thalidomide—Headache—Cyclosporine—psoriasis	1.97e-05	0.000144	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—psoriasis	1.97e-05	0.000144	CcSEcCtD
Thalidomide—Feeling abnormal—Betamethasone—psoriasis	1.97e-05	0.000144	CcSEcCtD
Thalidomide—Feeling abnormal—Dexamethasone—psoriasis	1.97e-05	0.000144	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dexamethasone—psoriasis	1.95e-05	0.000143	CcSEcCtD
Thalidomide—Gastrointestinal pain—Betamethasone—psoriasis	1.95e-05	0.000143	CcSEcCtD
Thalidomide—Vomiting—Mycophenolate mofetil—psoriasis	1.95e-05	0.000143	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB4—IL6—psoriasis	1.94e-05	0.000227	CbGpPWpGaD
Thalidomide—Hypersensitivity—Triamcinolone—psoriasis	1.94e-05	0.000142	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-A—psoriasis	1.94e-05	0.000227	CbGpPWpGaD
Thalidomide—Rash—Mycophenolate mofetil—psoriasis	1.93e-05	0.000142	CcSEcCtD
Thalidomide—Dermatitis—Mycophenolate mofetil—psoriasis	1.93e-05	0.000142	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—CRP—psoriasis	1.92e-05	0.000225	CbGpPWpGaD
Thalidomide—Headache—Mycophenolate mofetil—psoriasis	1.92e-05	0.000141	CcSEcCtD
Thalidomide—Malaise—Methotrexate—psoriasis	1.92e-05	0.000141	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—psoriasis	1.91e-05	0.00014	CcSEcCtD
Thalidomide—Diarrhoea—Hydrocortisone—psoriasis	1.91e-05	0.00014	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—IL6—psoriasis	1.91e-05	0.000223	CbGpPWpGaD
Thalidomide—Leukopenia—Methotrexate—psoriasis	1.91e-05	0.00014	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—VEGFA—psoriasis	1.9e-05	0.000222	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—TP53—psoriasis	1.9e-05	0.000222	CbGpPWpGaD
Thalidomide—Urticaria—Betamethasone—psoriasis	1.9e-05	0.000139	CcSEcCtD
Thalidomide—Urticaria—Dexamethasone—psoriasis	1.9e-05	0.000139	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—NDUFA5—psoriasis	1.9e-05	0.000222	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Prednisone—psoriasis	1.89e-05	0.000139	CcSEcCtD
Thalidomide—Dizziness—Prednisolone—psoriasis	1.89e-05	0.000139	CcSEcCtD
Thalidomide—CYP3A5—Metabolism—NDUFA5—psoriasis	1.89e-05	0.000221	CbGpPWpGaD
Thalidomide—Asthenia—Triamcinolone—psoriasis	1.89e-05	0.000138	CcSEcCtD
Thalidomide—Body temperature increased—Dexamethasone—psoriasis	1.89e-05	0.000138	CcSEcCtD
Thalidomide—Abdominal pain—Betamethasone—psoriasis	1.89e-05	0.000138	CcSEcCtD
Thalidomide—Abdominal pain—Dexamethasone—psoriasis	1.89e-05	0.000138	CcSEcCtD
Thalidomide—Body temperature increased—Betamethasone—psoriasis	1.89e-05	0.000138	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—STAT3—psoriasis	1.88e-05	0.00022	CbGpPWpGaD
Thalidomide—Insomnia—Prednisone—psoriasis	1.88e-05	0.000138	CcSEcCtD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	1.88e-05	0.00022	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.88e-05	0.00022	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.88e-05	0.00022	CbGpPWpGaD
Thalidomide—Nausea—Cyclosporine—psoriasis	1.87e-05	0.000137	CcSEcCtD
Thalidomide—Paraesthesia—Prednisone—psoriasis	1.87e-05	0.000137	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—NFKB1—psoriasis	1.86e-05	0.000218	CbGpPWpGaD
Thalidomide—Pruritus—Triamcinolone—psoriasis	1.86e-05	0.000136	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.86e-05	0.000218	CbGpPWpGaD
Thalidomide—Cough—Methotrexate—psoriasis	1.86e-05	0.000136	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—PPARG—psoriasis	1.86e-05	0.000217	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signal transduction—IL6—psoriasis	1.85e-05	0.000217	CbGpPWpGaD
Thalidomide—Dizziness—Hydrocortisone—psoriasis	1.85e-05	0.000135	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	1.85e-05	0.000216	CbGpPWpGaD
Thalidomide—Convulsion—Methotrexate—psoriasis	1.85e-05	0.000135	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR—IL6—psoriasis	1.84e-05	0.000216	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-A—psoriasis	1.84e-05	0.000215	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—IL6—psoriasis	1.83e-05	0.000215	CbGpPWpGaD
Thalidomide—Dyspepsia—Prednisone—psoriasis	1.83e-05	0.000134	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—CRP—psoriasis	1.83e-05	0.000214	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—IL6—psoriasis	1.83e-05	0.000214	CbGpPWpGaD
Thalidomide—Nausea—Mycophenolate mofetil—psoriasis	1.82e-05	0.000134	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—psoriasis	1.81e-05	0.000133	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—psoriasis	1.81e-05	0.000133	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—psoriasis	1.81e-05	0.000133	CcSEcCtD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.81e-05	0.000212	CbGpPWpGaD
Thalidomide—Decreased appetite—Prednisone—psoriasis	1.81e-05	0.000132	CcSEcCtD
Thalidomide—Rash—Prednisolone—psoriasis	1.8e-05	0.000132	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—psoriasis	1.8e-05	0.000132	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	1.8e-05	0.000132	CcSEcCtD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—STAT3—psoriasis	1.8e-05	0.00021	CbGpPWpGaD
Thalidomide—Fatigue—Prednisone—psoriasis	1.79e-05	0.000131	CcSEcCtD
Thalidomide—Headache—Prednisolone—psoriasis	1.79e-05	0.000131	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—psoriasis	1.79e-05	0.000131	CcSEcCtD
Thalidomide—CYP1A1—Metabolism—NDUFA5—psoriasis	1.79e-05	0.000209	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-E—psoriasis	1.78e-05	0.000208	CbGpPWpGaD
Thalidomide—Constipation—Prednisone—psoriasis	1.78e-05	0.00013	CcSEcCtD
Thalidomide—Vomiting—Hydrocortisone—psoriasis	1.78e-05	0.00013	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DRB1—psoriasis	1.77e-05	0.000207	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—STAT3—psoriasis	1.77e-05	0.000207	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—IL6—psoriasis	1.76e-05	0.000207	CbGpPWpGaD
Thalidomide—Rash—Hydrocortisone—psoriasis	1.76e-05	0.000129	CcSEcCtD
Thalidomide—Dermatitis—Hydrocortisone—psoriasis	1.76e-05	0.000129	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.76e-05	0.000206	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.76e-05	0.000206	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NFKBIA—psoriasis	1.76e-05	0.000205	CbGpPWpGaD
Thalidomide—Confusional state—Methotrexate—psoriasis	1.75e-05	0.000128	CcSEcCtD
Thalidomide—Headache—Hydrocortisone—psoriasis	1.75e-05	0.000128	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—CCL20—psoriasis	1.75e-05	0.000204	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	1.74e-05	0.000204	CbGpPWpGaD
Thalidomide—Dizziness—Triamcinolone—psoriasis	1.74e-05	0.000128	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—IL6—psoriasis	1.74e-05	0.000204	CbGpPWpGaD
Thalidomide—Infection—Methotrexate—psoriasis	1.73e-05	0.000127	CcSEcCtD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—psoriasis	1.72e-05	0.000201	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.72e-05	0.000201	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—IL6—psoriasis	1.72e-05	0.000201	CbGpPWpGaD
Thalidomide—Feeling abnormal—Prednisone—psoriasis	1.71e-05	0.000126	CcSEcCtD
Thalidomide—Asthenia—Dexamethasone—psoriasis	1.71e-05	0.000126	CcSEcCtD
Thalidomide—Asthenia—Betamethasone—psoriasis	1.71e-05	0.000126	CcSEcCtD
Thalidomide—PTGS2—Metabolism—CYP2S1—psoriasis	1.71e-05	0.0002	CbGpPWpGaD
Thalidomide—Nervous system disorder—Methotrexate—psoriasis	1.7e-05	0.000125	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—psoriasis	1.7e-05	0.000125	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR—IL6—psoriasis	1.7e-05	0.000199	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Prednisone—psoriasis	1.7e-05	0.000125	CcSEcCtD
Thalidomide—Nausea—Prednisolone—psoriasis	1.7e-05	0.000125	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—ICAM1—psoriasis	1.7e-05	0.000199	CbGpPWpGaD
Thalidomide—Pruritus—Dexamethasone—psoriasis	1.69e-05	0.000124	CcSEcCtD
Thalidomide—Pruritus—Betamethasone—psoriasis	1.69e-05	0.000124	CcSEcCtD
Thalidomide—FGFR2—Immune System—HLA-E—psoriasis	1.69e-05	0.000198	CbGpPWpGaD
Thalidomide—Skin disorder—Methotrexate—psoriasis	1.69e-05	0.000124	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—psoriasis	1.69e-05	0.000197	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NFKBIA—psoriasis	1.69e-05	0.000197	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Methotrexate—psoriasis	1.68e-05	0.000123	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DRB1—psoriasis	1.68e-05	0.000197	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—IL6—psoriasis	1.68e-05	0.000197	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—psoriasis	1.68e-05	0.000196	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—STAT3—psoriasis	1.67e-05	0.000196	CbGpPWpGaD
Thalidomide—Vomiting—Triamcinolone—psoriasis	1.67e-05	0.000123	CcSEcCtD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	1.67e-05	0.000196	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.67e-05	0.000195	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NFKBIA—psoriasis	1.67e-05	0.000195	CbGpPWpGaD
Thalidomide—Nausea—Hydrocortisone—psoriasis	1.66e-05	0.000122	CcSEcCtD
Thalidomide—Rash—Triamcinolone—psoriasis	1.66e-05	0.000122	CcSEcCtD
Thalidomide—Dermatitis—Triamcinolone—psoriasis	1.66e-05	0.000122	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—psoriasis	1.66e-05	0.000121	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—CCL20—psoriasis	1.66e-05	0.000194	CbGpPWpGaD
Thalidomide—Urticaria—Prednisone—psoriasis	1.65e-05	0.000121	CcSEcCtD
Thalidomide—Headache—Triamcinolone—psoriasis	1.65e-05	0.000121	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—psoriasis	1.64e-05	0.00012	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—psoriasis	1.64e-05	0.00012	CcSEcCtD
Thalidomide—Diarrhoea—Betamethasone—psoriasis	1.63e-05	0.00012	CcSEcCtD
Thalidomide—Diarrhoea—Dexamethasone—psoriasis	1.63e-05	0.00012	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—TYK2—psoriasis	1.63e-05	0.000191	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—LEP—psoriasis	1.63e-05	0.00019	CbGpPWpGaD
Thalidomide—Hypotension—Methotrexate—psoriasis	1.62e-05	0.000119	CcSEcCtD
Thalidomide—CYP2E1—Metabolism—CYP2S1—psoriasis	1.61e-05	0.000189	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ICAM1—psoriasis	1.61e-05	0.000189	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2S1—psoriasis	1.61e-05	0.000188	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NFKBIA—psoriasis	1.6e-05	0.000187	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Methotrexate—psoriasis	1.58e-05	0.000116	CcSEcCtD
Thalidomide—Dizziness—Dexamethasone—psoriasis	1.58e-05	0.000116	CcSEcCtD
Thalidomide—Dizziness—Betamethasone—psoriasis	1.58e-05	0.000116	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—psoriasis	1.57e-05	0.000115	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—psoriasis	1.57e-05	0.000184	CbGpPWpGaD
Thalidomide—Nausea—Triamcinolone—psoriasis	1.56e-05	0.000115	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—psoriasis	1.56e-05	0.000114	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—psoriasis	1.55e-05	0.000114	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—psoriasis	1.55e-05	0.000113	CcSEcCtD
Thalidomide—Hypersensitivity—Prednisone—psoriasis	1.53e-05	0.000112	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—psoriasis	1.53e-05	0.000112	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—psoriasis	1.53e-05	0.000179	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.52e-05	0.000178	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2S1—psoriasis	1.52e-05	0.000178	CbGpPWpGaD
Thalidomide—Vomiting—Dexamethasone—psoriasis	1.52e-05	0.000111	CcSEcCtD
Thalidomide—Vomiting—Betamethasone—psoriasis	1.52e-05	0.000111	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—psoriasis	1.51e-05	0.000111	CcSEcCtD
Thalidomide—Rash—Dexamethasone—psoriasis	1.51e-05	0.00011	CcSEcCtD
Thalidomide—Rash—Betamethasone—psoriasis	1.51e-05	0.00011	CcSEcCtD
Thalidomide—Dermatitis—Dexamethasone—psoriasis	1.5e-05	0.00011	CcSEcCtD
Thalidomide—Dermatitis—Betamethasone—psoriasis	1.5e-05	0.00011	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—psoriasis	1.5e-05	0.00011	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—psoriasis	1.5e-05	0.00011	CcSEcCtD
Thalidomide—Headache—Dexamethasone—psoriasis	1.5e-05	0.00011	CcSEcCtD
Thalidomide—Headache—Betamethasone—psoriasis	1.5e-05	0.00011	CcSEcCtD
Thalidomide—Asthenia—Prednisone—psoriasis	1.49e-05	0.000109	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	1.49e-05	0.000175	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SOCS1—psoriasis	1.49e-05	0.000174	CbGpPWpGaD
Thalidomide—Pain—Methotrexate—psoriasis	1.49e-05	0.000109	CcSEcCtD
Thalidomide—Pruritus—Prednisone—psoriasis	1.47e-05	0.000108	CcSEcCtD
Thalidomide—CYP2C19—Metabolism—NDUFA5—psoriasis	1.46e-05	0.000171	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—psoriasis	1.46e-05	0.000171	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—TYK2—psoriasis	1.44e-05	0.000168	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—psoriasis	1.44e-05	0.000168	CbGpPWpGaD
Thalidomide—Feeling abnormal—Methotrexate—psoriasis	1.43e-05	0.000105	CcSEcCtD
Thalidomide—Diarrhoea—Prednisone—psoriasis	1.42e-05	0.000104	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—psoriasis	1.42e-05	0.000104	CcSEcCtD
Thalidomide—Nausea—Betamethasone—psoriasis	1.42e-05	0.000104	CcSEcCtD
Thalidomide—Nausea—Dexamethasone—psoriasis	1.42e-05	0.000104	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.42e-05	0.000166	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—PPARG—psoriasis	1.42e-05	0.000166	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SOCS1—psoriasis	1.41e-05	0.000165	CbGpPWpGaD
Thalidomide—Urticaria—Methotrexate—psoriasis	1.38e-05	0.000101	CcSEcCtD
Thalidomide—Dizziness—Prednisone—psoriasis	1.38e-05	0.000101	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—psoriasis	1.37e-05	0.000101	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—psoriasis	1.37e-05	0.000101	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—TYK2—psoriasis	1.36e-05	0.00016	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.36e-05	0.00016	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NDUFA5—psoriasis	1.33e-05	0.000156	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.33e-05	0.000155	CbGpPWpGaD
Thalidomide—Vomiting—Prednisone—psoriasis	1.32e-05	9.69e-05	CcSEcCtD
Thalidomide—NFKB1—Immune System—CD8A—psoriasis	1.32e-05	0.000154	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—psoriasis	1.31e-05	0.000154	CbGpPWpGaD
Thalidomide—Rash—Prednisone—psoriasis	1.31e-05	9.61e-05	CcSEcCtD
Thalidomide—Dermatitis—Prednisone—psoriasis	1.31e-05	9.6e-05	CcSEcCtD
Thalidomide—Headache—Prednisone—psoriasis	1.3e-05	9.55e-05	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—CD4—psoriasis	1.3e-05	0.000152	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.29e-05	0.000151	CbGpPWpGaD
Thalidomide—Hypersensitivity—Methotrexate—psoriasis	1.28e-05	9.39e-05	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.28e-05	0.00015	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-B—psoriasis	1.27e-05	0.000148	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—psoriasis	1.25e-05	0.000147	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—psoriasis	1.25e-05	0.000146	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—psoriasis	1.25e-05	0.000146	CbGpPWpGaD
Thalidomide—Asthenia—Methotrexate—psoriasis	1.25e-05	9.14e-05	CcSEcCtD
Thalidomide—CYP2C19—Metabolism—CYP2S1—psoriasis	1.24e-05	0.000146	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.24e-05	0.000146	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TYK2—psoriasis	1.24e-05	0.000145	CbGpPWpGaD
Thalidomide—Nausea—Prednisone—psoriasis	1.24e-05	9.05e-05	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—CD4—psoriasis	1.23e-05	0.000144	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—psoriasis	1.23e-05	0.000144	CbGpPWpGaD
Thalidomide—Pruritus—Methotrexate—psoriasis	1.23e-05	9.01e-05	CcSEcCtD
Thalidomide—FGFR2—Immune System—HLA-B—psoriasis	1.2e-05	0.000141	CbGpPWpGaD
Thalidomide—Diarrhoea—Methotrexate—psoriasis	1.19e-05	8.72e-05	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD4—psoriasis	1.18e-05	0.000139	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.18e-05	0.000138	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-A—psoriasis	1.18e-05	0.000138	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—psoriasis	1.17e-05	0.000137	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—JUN—psoriasis	1.16e-05	0.000136	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.16e-05	0.000136	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—psoriasis	1.15e-05	0.000135	CbGpPWpGaD
Thalidomide—Dizziness—Methotrexate—psoriasis	1.15e-05	8.42e-05	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—STAT3—psoriasis	1.14e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NDUFA5—psoriasis	1.14e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2S1—psoriasis	1.13e-05	0.000133	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.13e-05	0.000132	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—psoriasis	1.12e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-A—psoriasis	1.12e-05	0.000131	CbGpPWpGaD
Thalidomide—Vomiting—Methotrexate—psoriasis	1.11e-05	8.1e-05	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—JUN—psoriasis	1.1e-05	0.000129	CbGpPWpGaD
Thalidomide—Rash—Methotrexate—psoriasis	1.1e-05	8.03e-05	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—psoriasis	1.09e-05	8.02e-05	CcSEcCtD
Thalidomide—Headache—Methotrexate—psoriasis	1.09e-05	7.98e-05	CcSEcCtD
Thalidomide—NFKB1—Immune System—HLA-DRB1—psoriasis	1.07e-05	0.000126	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—psoriasis	1.06e-05	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NFKB1—psoriasis	1.06e-05	0.000124	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.06e-05	0.000124	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CARM1—psoriasis	1.05e-05	0.000123	CbGpPWpGaD
Thalidomide—Nausea—Methotrexate—psoriasis	1.03e-05	7.57e-05	CcSEcCtD
Thalidomide—NFKB1—Immune System—ICAM1—psoriasis	1.03e-05	0.000121	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HLA-A—psoriasis	1.03e-05	0.000121	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NFKBIA—psoriasis	1.02e-05	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NFKB1—psoriasis	1.02e-05	0.000119	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—psoriasis	1.02e-05	0.000119	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	9.94e-06	0.000116	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—psoriasis	9.87e-06	0.000115	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.85e-06	0.000115	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ICAM1—psoriasis	9.78e-06	0.000114	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NFKBIA—psoriasis	9.7e-06	0.000114	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2S1—psoriasis	9.69e-06	0.000113	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NFKB1—psoriasis	9.66e-06	0.000113	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SOCS1—psoriasis	9.61e-06	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APOE—psoriasis	9.61e-06	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SOCS1—psoriasis	9.12e-06	0.000107	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.98e-06	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS2—psoriasis	8.96e-06	0.000105	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—psoriasis	8.77e-06	0.000103	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	8.77e-06	0.000103	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—STAT3—psoriasis	8.68e-06	0.000102	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TYK2—psoriasis	8.37e-06	9.8e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CARM1—psoriasis	8.36e-06	9.79e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.97e-06	9.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—psoriasis	7.96e-06	9.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TYK2—psoriasis	7.95e-06	9.3e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CARM1—psoriasis	7.87e-06	9.22e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CARM1—psoriasis	7.86e-06	9.2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—psoriasis	7.84e-06	9.18e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.82e-06	9.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—psoriasis	7.57e-06	8.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—psoriasis	7.44e-06	8.71e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CARM1—psoriasis	7.42e-06	8.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TYK2—psoriasis	7.34e-06	8.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—psoriasis	7.19e-06	8.41e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APOE—psoriasis	7.09e-06	8.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—psoriasis	7.09e-06	8.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—psoriasis	7.03e-06	8.23e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.94e-06	8.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—JUN—psoriasis	6.78e-06	7.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—psoriasis	6.73e-06	7.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—psoriasis	6.73e-06	7.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—psoriasis	6.67e-06	7.81e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—psoriasis	6.63e-06	7.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NFKBIA—psoriasis	6.61e-06	7.74e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.52e-06	7.63e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAT—psoriasis	6.48e-06	7.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—JUN—psoriasis	6.43e-06	7.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKBIA—psoriasis	6.27e-06	7.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NFKB1—psoriasis	6.19e-06	7.25e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CARM1—psoriasis	6.07e-06	7.11e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—psoriasis	6.07e-06	7.1e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.94e-06	6.96e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—STAT3—psoriasis	5.86e-06	6.86e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.68e-06	6.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—psoriasis	5.56e-06	6.51e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CARM1—psoriasis	5.54e-06	6.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TYK2—psoriasis	5.41e-06	6.34e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.18e-06	6.06e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAT—psoriasis	5.14e-06	6.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TYK2—psoriasis	5.14e-06	6.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—psoriasis	5.14e-06	6.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—psoriasis	5.11e-06	5.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.08e-06	5.95e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—psoriasis	5.04e-06	5.89e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAT—psoriasis	4.84e-06	5.67e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAT—psoriasis	4.83e-06	5.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—psoriasis	4.77e-06	5.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CARM1—psoriasis	4.73e-06	5.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—psoriasis	4.71e-06	5.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAT—psoriasis	4.57e-06	5.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—psoriasis	4.47e-06	5.24e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—psoriasis	4.45e-06	5.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.42e-06	5.18e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—psoriasis	4.39e-06	5.13e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—psoriasis	4.38e-06	5.13e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—psoriasis	4.16e-06	4.87e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—psoriasis	4.1e-06	4.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKB1—psoriasis	4e-06	4.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—psoriasis	4e-06	4.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—psoriasis	3.89e-06	4.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—psoriasis	3.83e-06	4.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—psoriasis	3.79e-06	4.44e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—psoriasis	3.76e-06	4.4e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—psoriasis	3.76e-06	4.4e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAT—psoriasis	3.74e-06	4.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TYK2—psoriasis	3.64e-06	4.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—psoriasis	3.63e-06	4.25e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—psoriasis	3.6e-06	4.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—psoriasis	3.59e-06	4.2e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—psoriasis	3.55e-06	4.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—psoriasis	3.48e-06	4.08e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAT—psoriasis	3.41e-06	3.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—psoriasis	3.29e-06	3.86e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—psoriasis	3.28e-06	3.84e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—psoriasis	3.27e-06	3.83e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—psoriasis	3.09e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAT—psoriasis	2.91e-06	3.41e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—psoriasis	2.9e-06	3.4e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—psoriasis	2.89e-06	3.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—psoriasis	2.74e-06	3.21e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—psoriasis	2.65e-06	3.1e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—psoriasis	2.65e-06	3.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—psoriasis	2.55e-06	2.99e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—psoriasis	2.53e-06	2.96e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—psoriasis	2.51e-06	2.94e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—psoriasis	2.31e-06	2.7e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—psoriasis	2.26e-06	2.65e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—psoriasis	1.97e-06	2.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—psoriasis	1.78e-06	2.09e-05	CbGpPWpGaD
